Literature DB >> 2270317

Metabolic clearance rates of oxyntomodulin and glucagon in the rat: contribution of the kidney.

A Kervran1, M Dubrasquet, P Blache, J Martinez, D Bataille.   

Abstract

The half-life (t1/2) and metabolic clearance rate (MCR) of exogenous natural porcine oxyntomodulin (porcine OXM) and the synthetic analog of rat oxyntomodulin, [Nle27]-OXM (rat OXM), were compared with that of glucagon in control, sham-operated and acutely nephrectomized rats using the primed-continuous infusion technique. The half-disappearance times for porcine OXM (8.2 +/- 0.5 min) and rat OXM (6.4 +/- 0.5 min) were 3-fold slower than that of glucagon (1.9 +/- 0.1 min). Acute bilateral nephrectomy significantly prolonged the half-disappearance time of rat OXM (8.2 +/- 0.7 min) and glucagon (3.6 +/- 0.4 min) compared with that of sham-operated animals (6.5 +/- 0.8 min and 2.5 +/- 0.2 min, respectively). The mean MCRs were similar for porcine and rat OXM (11.3 +/- 0.7 and 11.9 +/- 0.5 ml.kg-1.min-1) but were 3 times lower than that measured with glucagon (36 +/- 5 ml.kg-1.min-1). Bilateral nephrectomy reduced the MCR of OXM and glucagon by 38% and 34%, respectively. No significant increase in C-terminal glucagon immunoreactivity was noticed during infusion of either porcine or rat OXM, measured directly in plasma, with a specific C-terminal glucagon antiserum or after HPLC. In the course of the glucagon infusion, blood glucose was increased 2-fold, while the same dose of porcine OXM or of rat OXM induced only a small increase over the values in phosphate buffer-infused rats. 10 times higher doses of rat OXM were necessary to obtain a similar hyperglycemic effect. These results indicate that: (1) the metabolism of OXM is 3-fold slower than that of glucagon, (2) renal clearance contributed close to 35% of the overall metabolic plasma extraction for OXM and glucagon and (3) OXM, although effective at a higher dose, when compared with glucagon, displays a hyperglycemic effect probably through the glucagon receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2270317     DOI: 10.1016/0167-0115(90)90194-2

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  12 in total

1.  Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke.

Authors:  Yazhou Li; Kou-Jen Wu; Seong-Jin Yu; Ian A Tamargo; Yun Wang; Nigel H Greig
Journal:  Exp Neurol       Date:  2016-11-14       Impact factor: 5.330

2.  N-acetyl oxyntomodulin30-37: pharmacokinetics and activity on gastric acid secretion.

Authors:  C Carles-Bonnet; C Jarrousse; H Niel; J Martinez; M Rolland; D Bataille
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-01       Impact factor: 3.000

3.  Glucagon clearance is regulated by nutritional state: evidence from experimental studies in mice.

Authors:  Alyssa Zhou; Giovanni Pacini; Bo Ahrén; David Z D'Argenio
Journal:  Diabetologia       Date:  2013-12-28       Impact factor: 10.122

Review 4.  Unraveling oxyntomodulin, GLP1's enigmatic brother.

Authors:  Alessandro Pocai
Journal:  J Endocrinol       Date:  2012-09-27       Impact factor: 4.286

5.  Normal glucagon signaling and β-cell function after near-total α-cell ablation in adult mice.

Authors:  Fabrizio Thorel; Nicolas Damond; Simona Chera; Andreas Wiederkehr; Bernard Thorens; Paolo Meda; Claes B Wollheim; Pedro L Herrera
Journal:  Diabetes       Date:  2011-09-16       Impact factor: 9.461

6.  Degradation and Stabilization of Peptide Hormones in Human Blood Specimens.

Authors:  Jizu Yi; David Warunek; David Craft
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

7.  Increased food intake with oxyntomodulin analogues.

Authors:  Samantha L Price; James S Minnion; Stephen R Bloom
Journal:  Peptides       Date:  2015-09-30       Impact factor: 3.750

8.  Gene Therapy Induces Antigen-Specific Tolerance in Experimental Collagen-Induced Arthritis.

Authors:  Sara Tengvall; Tove Eneljung; Pernilla Jirholt; Olof Turesson; Kajsa Wing; Rikard Holmdahl; Jan Kihlberg; Anna Stern; Inga-Lill Mårtensson; Louise Henningsson; Kenth Gustafsson; Inger Gjertsson
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240

9.  Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.

Authors:  Alessandro Pocai; Paul E Carrington; Jennifer R Adams; Michael Wright; George Eiermann; Lan Zhu; Xiaobing Du; Aleksandr Petrov; Michael E Lassman; Guoqiang Jiang; Franklin Liu; Corey Miller; Laurie M Tota; Gaochao Zhou; Xiaoping Zhang; Michael M Sountis; Alessia Santoprete; Elena Capito'; Gary G Chicchi; Nancy Thornberry; Elisabetta Bianchi; Antonello Pessi; Donald J Marsh; Ranabir SinhaRoy
Journal:  Diabetes       Date:  2009-07-14       Impact factor: 9.461

10.  Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats.

Authors:  Samantha L Price; James S Minnion; Stephen R Bloom
Journal:  Curr Ther Res Clin Exp       Date:  2015-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.